Anti-CTLA-4 agents were the first ICIs that were considered effective for cancer treatment, and ipilimumab was the first approved anti-CTLA-4 monoclonal antibody (mAb) for metastatic melanoma [11]. The gene discussed is CTLA4; the disease is metastatic melanoma.